In addition, DPP4 inhibitors have shown a neutral effect in most CV outcome trials [13, 14], and they have a moderate effect in reducing HbA1c with a low risk of hypoglycemia similar to SGLT2 inhibitors [15]. Here, SLC5A2 is linked to Hypoglycemia.